Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $23,505.79 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 26,411 shares of the stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $0.89, for a total transaction of $23,505.79. Following the completion of the sale, the director directly owned 3,413,127 shares of the company’s stock, valued at approximately $3,037,683.03. This trade represents a 0.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Luke Evnin also recently made the following trade(s):

• On Wednesday, November 19th, Luke Evnin sold 42,566 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.94, for a total transaction of $40,012.04.
• On Tuesday, November 18th, Luke Evnin sold 33,776 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.93, for a total transaction of $31,411.68.
• On Monday, November 17th, Luke Evnin sold 36,621 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.95, for a total value of $34,789.95.
• On Friday, November 14th, Luke Evnin sold 39,560 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.93, for a total value of $36,790.80.
• On Thursday, November 13th, Luke Evnin sold 58,372 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.98, for a total value of $57,204.56.
• On Wednesday, November 12th, Luke Evnin sold 26,101 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.09, for a total value of $28,450.09.
• On Tuesday, November 11th, Luke Evnin sold 35,818 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.14, for a total value of $40,832.52.
• On Monday, November 10th, Luke Evnin sold 31,172 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.18, for a total value of $36,782.96.
• On Friday, November 7th, Luke Evnin sold 43,950 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.11, for a total value of $48,784.50.
• On Thursday, November 6th, Luke Evnin sold 34,947 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.21, for a total transaction of $42,285.87.

Werewolf Therapeutics Price Performance

HOWL stock opened at $0.87 on Friday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.87 and a current ratio of 3.87. The company’s fifty day moving average price is $1.52 and its 200-day moving average price is $1.33. Werewolf Therapeutics, Inc. has a one year low of $0.60 and a one year high of $2.38. The company has a market capitalization of $42.39 million, a PE ratio of -0.54 and a beta of 0.72.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.03. On average, equities analysts anticipate that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

Institutional Investors Weigh In On Werewolf Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. boosted its holdings in shares of Werewolf Therapeutics by 33.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company’s stock worth $93,000 after purchasing an additional 23,852 shares during the period. Nuveen LLC bought a new stake in Werewolf Therapeutics in the first quarter worth $71,000. MPM Asset Management LLC lifted its position in Werewolf Therapeutics by 0.6% in the first quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock worth $4,189,000 after buying an additional 25,688 shares during the last quarter. MPM Bioimpact LLC boosted its stake in Werewolf Therapeutics by 0.9% during the first quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock worth $2,341,000 after buying an additional 20,799 shares during the period. Finally, AQR Capital Management LLC bought a new position in Werewolf Therapeutics during the first quarter valued at $79,000. 64.84% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

HOWL has been the topic of several research reports. Citigroup reaffirmed a “market outperform” rating on shares of Werewolf Therapeutics in a report on Wednesday, November 12th. Bank of America cut their price target on Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a report on Tuesday, November 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th. JMP Securities lowered their target price on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research report on Thursday, August 21st. Finally, Zacks Research raised shares of Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 16th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $7.75.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.